Validation of mammalian target of rapamycin biomarker panel in patients with clear cell renal cell carcinoma

By Haddad Ahmed Q.   Kapur Payal   Singla Nirmish   Raman Jay D.   Then Matthew T.   Nuhn Philipp   Buchner Alexander   Bastian Patrick   Seitz Christian   Shariat Shahrokh F.   Bensalah Karim   Rioux-Leclercq Nathalie   Sagalowsky Arthur   Lotan Yair   Margulis Vitaly  

Cancer, Vol. 121, Iss. 1, 2015-01 ,pp. : 43-50

Blackwell Publishing

Access to resources Recommend Favorite

Mechanisms of Acquired Resistance to Tyrosine Kinase Inhibitors in Clear - Cell Renal Cell Carcinoma (ccRCC)

By  

Current Signal Transduction Therapy, Vol. 8, Iss. 3, 2013-12 ,pp. : 219-228

Bentham Science Publishers

Access to resources Recommend Favorite

Future directions of mammalian target of rapamycin (mTOR) inhibitor therapy in renal cell carcinoma

By Pal Sumanta  

Targeted Oncology, Vol. 6, Iss. 1, 2011-03 ,pp. : 5-16

Springer Publishing Company

Access to resources Recommend Favorite

Mechanisms of Cisplatin Resistance in Clear Cell Carcinoma of the Ovary

By  

Oncology, Vol. 62, Iss. 4, 2002-07 ,pp. : 349-353

Karger

Access to resources Recommend Favorite

Successful mammalian target of rapamycin inhibitor maintenance therapy following induction chemotherapy with gemcitabine and doxorubicin for metastatic sarcomatoid renal cell carcinoma

By                

Oncology Letters, Vol. 8, Iss. 1, 2014-01 ,pp. : 464-466

Spandidos Publications

Access to resources Recommend Favorite